| Description |
| Product Type |
Product Size |
| Injection
|
1'S |
| Product Company |
| GP Pharm |
Leuprorelin Acetate 22.5mg
|
| Product Type |
Product Size |
| Tablets |
30'S |
| Product Company |
| Beacon Pharmaceuticals |
Sorafenib 200mg |
| Product Type |
Product Size |
| injection |
1'S |
| Product Company |
| Pharmedic |
Dacarbazine 200mg |
| Product Type |
Product Size |
| Tablets |
28'S |
| Product Company |
| Himmel Pharma |
Bicalutamide 50mg |
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Roche Pharma |
Atezolizumab 1200mg/20ml |
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Roche Pharma |
Bevacizumab 400mg/16ml |
| Content | Leuprolide is a peptide-based GnRH receptor superagonist used for the palliative treatment of prostate cancer, uterine leiomyomata, endometriosis, and central precocious puberty."
| Sorafenib is used to treat late-stage kidney cancer (advanced renal cell carcinoma), liver cancer (hepatocellular carcinoma) that cannot be treated by surgery, and differentiated thyroid cancer that has come back or spread to other parts of your body. Sorafenib is an antineoplastic (cancer) agent.
| Dacarbazine, also known as imidazole carboxamide, is a chemotherapy medication used in the treatment of melanoma and Hodgkin's lymphoma. For Hodgkin's it is often used together with vinblastine, bleomycin, and doxorubicin. | Bicalutamide belongs to the group of medicines called antiandrogens. It works by blocking the effects of testosterone (a male hormone), which helps stop the growth and spread of cancer cells.
| "
Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, small cell lung cancer, hepatocellular carcinoma, and alveolar soft part sarcoma. | "
Bevacizumab is a type of targeted cancer drug treatment. It is also known as Avastin. It is a treatment for a number of different cancer types. |
Reviews
There are no reviews yet.